We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Merges Patient Data with Blood Test Results to Detect Heart Failure

By LabMedica International staff writers
Posted on 20 Jun 2022

Acute heart failure is a life-threatening condition caused when the heart is suddenly unable to pump blood around the body. More...

It affects millions of people and accounts for a large percentage of all unplanned hospital admissions. Diagnosis is difficult because symptoms, such as shortness of breath and leg swelling, occur in many other illnesses. Previous research has shown that patients who are diagnosed quickly benefit the most from treatment. Now, research suggests that using artificial intelligence (AI) can help diagnose acute heart failure with more accuracy than current blood tests alone.

The research conducted by The University of Edinburgh (Edinburgh, UK) found that using AI to combine patient data with results from a test for levels of a protein made by the heart could help doctors spot heart failure sooner and improve patient care. Researchers combined data from 10,369 patients with suspected acute heart failure to develop a tool - called CoDE-HF – to inform clinicians’ decisions. CoDE-HF uses AI to combine routinely collected patient information with results from a blood test for the heart protein NT-proBNP to produce an estimate of whether they suffered heart failure. The current recommended diagnosis method is to test to see if levels of NT-proBNP are below a certain cut-off value, but this is not widely used as levels can vary depending on an individual’s age, weight and other health conditions.

As well as spotting acute heart failure more accurately than heart protein blood tests on their own, CoDE-HF was especially precise in difficult to diagnose patient groups - such as older people and those with pre-existing medical conditions. The team is currently conducting further studies to understand how this decision-support tool will work in the hospital environment and influence patient outcomes.

“Heart failure can be a very challenging diagnosis to make in practice. We have shown that CoDE-HF, our decision-support tool, can substantially improve the accuracy of diagnosing heart failure compared to current blood tests,” said Dr. Ken Lee, cardiology specialist registrar and clinical lecturer at the University of Edinburgh.

“Our study demonstrates that the application of artificial intelligence in healthcare has major potential to help doctors deliver more personalized patient care,” added Dimitrios Doudesis, research fellow and data scientist at the University of Edinburgh.

“The application of artificial intelligence in decision-support tools as CoDE-HF to deliver more personalized care is particularly important given our ageing patient population who are living longer with more pre-existing medical conditions. We are currently conducting further studies to identify ways to implement CoDE-HF effectively in routine care,” stated Professor Nicholas Mills, British Heart Foundation professor of cardiology at the University of Edinburgh and consultant cardiologist.

Related Links:
The University of Edinburgh 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.